Glaxosmithkline Plc Adr Stock Beta

GSK Stock

USD 40.86 0.38 0.92%

GlaxoSmithKline PLC ADR fundamentals help investors to digest information that contributes to GlaxoSmithKline PLC's financial success or failures. It also enables traders to predict the movement of GlaxoSmithKline Stock. The fundamental analysis module provides a way to measure GlaxoSmithKline PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GlaxoSmithKline PLC stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

GlaxoSmithKline PLC ADR Company Beta Analysis

GlaxoSmithKline PLC's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Beta

Covariance

Variance

More About Beta | All Equity Analysis

Current GlaxoSmithKline PLC Beta

0.27

Most of GlaxoSmithKline PLC's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline PLC ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

GlaxoSmithKline Beta Driver Correlations

Understanding the fundamental principles of building solid financial models for GlaxoSmithKline PLC is extremely important. It helps to project a fair market value of GlaxoSmithKline Stock properly, considering its historical fundamentals such as Beta. Since GlaxoSmithKline PLC's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of GlaxoSmithKline PLC's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of GlaxoSmithKline PLC's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Capital Stock	Short Term Debt	Common Stock	Retained Earnings	Intangible Assets	Long Term Debt	Good Will	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Treasury Stock	Net Tangible Assets	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital	Cash And Equivalents
Total Assets		0.5	0.9	0.77	-0.07	0.97	0.91	0.7	0.71	0.7	0.12	0.94	0.5	0.95	-0.16	0.23	0.56	0.19	-0.26	0.57	-0.59	0.59	0.4	0.49	0.5	0.2
Total Stockholder Equity	0.5		0.43	0.1	0.39	0.31	0.48	0.33	0.25	0.33	0.88	0.51	0.38	0.68	-0.23	0.1	0.69	0.13	0.06	0.75	-0.27	0.78	0.7	0.42	0.82	-0.44
Net Debt	0.9	0.43		0.7	-0.09	0.89	0.82	0.65	0.9	0.65	0.08	0.82	0.64	0.84	0.02	0.2	0.5	0.11	-0.05	0.47	-0.49	0.65	0.32	0.58	0.5	0.24
Accounts Payable	0.77	0.1	0.7		-0.1	0.82	0.67	0.53	0.59	0.53	-0.23	0.74	0.35	0.69	-0.06	0.31	0.39	0.09	-0.15	0.39	-0.51	0.27	0.08	0.13	0.24	0.37
Short Term Investments	-0.07	0.39	-0.09	-0.1		-0.09	0.13	0.0	-0.09	0.0	0.42	-0.18	-0.24	0.03	-0.51	0.18	0.39	0.27	0.21	0.54	-0.27	0.11	0.67	-0.19	0.61	-0.51
Total Liab	0.97	0.31	0.89	0.82	-0.09		0.91	0.74	0.75	0.74	-0.11	0.88	0.47	0.86	-0.15	0.23	0.45	0.2	-0.27	0.48	-0.63	0.46	0.33	0.42	0.4	0.25
Total Current Assets	0.91	0.48	0.82	0.67	0.13	0.91		0.88	0.65	0.88	0.06	0.72	0.6	0.79	-0.04	-0.04	0.4	0.15	-0.2	0.48	-0.54	0.41	0.41	0.31	0.47	0.13
Capital Stock	0.7	0.33	0.65	0.53	0.0	0.74	0.88		0.55	1.0	-0.14	0.49	0.74	0.55	0.23	-0.33	0.1	0.03	-0.16	0.25	-0.4	0.18	0.21	0.14	0.21	-0.02
Short Term Debt	0.71	0.25	0.9	0.59	-0.09	0.75	0.65	0.55		0.55	-0.03	0.65	0.56	0.66	0.12	0.25	0.42	-0.1	0.14	0.34	-0.31	0.55	0.19	0.53	0.37	0.21
Common Stock	0.7	0.33	0.65	0.53	0.0	0.74	0.88	1.0	0.55		-0.14	0.49	0.74	0.55	0.23	-0.33	0.1	0.03	-0.16	0.25	-0.4	0.18	0.21	0.14	0.21	-0.02
Retained Earnings	0.12	0.88	0.08	-0.23	0.42	-0.11	0.06	-0.14	-0.03	-0.14		0.2	0.03	0.37	-0.29	0.18	0.63	0.03	0.2	0.6	0.02	0.66	0.6	0.32	0.7	-0.44
Intangible Assets	0.94	0.51	0.82	0.74	-0.18	0.88	0.72	0.49	0.65	0.49	0.2		0.38	0.96	-0.26	0.4	0.61	0.22	-0.31	0.61	-0.57	0.7	0.35	0.57	0.51	0.14
Long Term Debt	0.5	0.38	0.64	0.35	-0.24	0.47	0.6	0.74	0.56	0.74	0.03	0.38		0.44	0.65	-0.46	0.02	-0.19	0.1	0.03	-0.06	0.29	-0.08	0.25	0.12	0.13
Good Will	0.95	0.68	0.84	0.69	0.03	0.86	0.79	0.55	0.66	0.55	0.37	0.96	0.44		-0.26	0.36	0.73	0.21	-0.17	0.73	-0.58	0.76	0.52	0.56	0.67	0.03
Property Plant Equipment	-0.16	-0.23	0.02	-0.06	-0.51	-0.15	-0.04	0.23	0.12	0.23	-0.29	-0.26	0.65	-0.26		-0.65	-0.46	-0.59	0.35	-0.64	0.54	-0.34	-0.65	-0.17	-0.56	0.39
Current Deferred Revenue	0.23	0.1	0.2	0.31	0.18	0.23	-0.04	-0.33	0.25	-0.33	0.18	0.4	-0.46	0.36	-0.65		0.7	0.16	0.21	0.57	-0.42	0.46	0.45	0.35	0.49	-0.12
Net Receivables	0.56	0.69	0.5	0.39	0.39	0.45	0.4	0.1	0.42	0.1	0.63	0.61	0.02	0.73	-0.46	0.7		0.02	0.33	0.85	-0.41	0.72	0.77	0.4	0.81	-0.23
Treasury Stock	0.19	0.13	0.11	0.09	0.27	0.2	0.15	0.03	-0.1	0.03	0.03	0.22	-0.19	0.21	-0.59	0.16	0.02		-0.5	0.37	-0.78	0.22	0.34	0.1	0.33	-0.23
Net Tangible Assets	-0.26	0.06	-0.05	-0.15	0.21	-0.27	-0.2	-0.16	0.14	-0.16	0.2	-0.31	0.1	-0.17	0.35	0.21	0.33	-0.5		0.04	0.24	0.01	0.15	-0.04	0.12	-0.13
Long Term Investments	0.57	0.75	0.47	0.39	0.54	0.48	0.48	0.25	0.34	0.25	0.6	0.61	0.03	0.73	-0.64	0.57	0.85	0.37	0.04		-0.65	0.76	0.88	0.45	0.92	-0.52
Short Long Term Debt	-0.59	-0.27	-0.49	-0.51	-0.27	-0.63	-0.54	-0.4	-0.31	-0.4	0.02	-0.57	-0.06	-0.58	0.54	-0.42	-0.41	-0.78	0.24	-0.65		-0.4	-0.56	-0.25	-0.53	0.24
Long Term Debt Total	0.59	0.78	0.65	0.27	0.11	0.46	0.41	0.18	0.55	0.18	0.66	0.7	0.29	0.76	-0.34	0.46	0.72	0.22	0.01	0.76	-0.4		0.6	0.81	0.83	-0.29
Capital Surpluse	0.4	0.7	0.32	0.08	0.67	0.33	0.41	0.21	0.19	0.21	0.6	0.35	-0.08	0.52	-0.65	0.45	0.77	0.34	0.15	0.88	-0.56	0.6		0.36	0.87	-0.59
Net Invested Capital	0.49	0.42	0.58	0.13	-0.19	0.42	0.31	0.14	0.53	0.14	0.32	0.57	0.25	0.56	-0.17	0.35	0.4	0.1	-0.04	0.45	-0.25	0.81	0.36		0.52	-0.1
Net Working Capital	0.5	0.82	0.5	0.24	0.61	0.4	0.47	0.21	0.37	0.21	0.7	0.51	0.12	0.67	-0.56	0.49	0.81	0.33	0.12	0.92	-0.53	0.83	0.87	0.52		-0.47
Cash And Equivalents	0.2	-0.44	0.24	0.37	-0.51	0.25	0.13	-0.02	0.21	-0.02	-0.44	0.14	0.13	0.03	0.39	-0.12	-0.23	-0.23	-0.13	-0.52	0.24	-0.29	-0.59	-0.1	-0.47

Click cells to compare fundamentals

In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Competition

Predict GlaxoSmithKline PLC

In accordance with the recently published financial statements, GlaxoSmithKline PLC ADR has a Beta of 0.268. This is 68.84% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.

GlaxoSmithKline Beta Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline PLC's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline PLC could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline PLC by comparing valuation metrics of similar companies.

GlaxoSmithKline PLC is currently under evaluation in beta category among related companies.

GlaxoSmithKline PLC Current Valuation Drivers

We derive many important indicators used in calculating different scores of GlaxoSmithKline PLC from analyzing GlaxoSmithKline PLC's financial statements. These drivers represent accounts that assess GlaxoSmithKline PLC's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of GlaxoSmithKline PLC's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	140.2B	107.2B	104.6B	117.3B	118.1B	124.0B
Enterprise Value	166.0B	128.0B	124.5B	134.6B	133.2B	139.8B

GlaxoSmithKline PLC Institutional Holders

Institutional Holdings refers to the ownership stake in GlaxoSmithKline PLC that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of GlaxoSmithKline PLC's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing GlaxoSmithKline PLC's value.

		Shares
Arrowstreet Capital Limited Partnership	2023-12-31	4.8 M
Mondrian Investment Partners Ltd	2023-12-31	4 M
Provident Trust Company	2023-12-31	3.7 M
Equity Investment Corp	2023-12-31	3.2 M
Eversept Partners, Llc	2023-12-31	3 M
Renaissance Technologies Corp	2023-12-31	2.8 M
Hotchkis & Wiley Capital Management Llc	2023-12-31	2.7 M
Hsbc Holdings Plc	2023-12-31	2.5 M
Wells Fargo & Co	2023-12-31	2.5 M
Dodge & Cox	2023-12-31	69 M
Fmr Inc	2023-12-31	19.4 M

As returns on the market increase, GlaxoSmithKline PLC's returns are expected to increase less than the market. However, during the bear market, the loss of holding GlaxoSmithKline PLC is expected to be smaller as well.

GlaxoSmithKline Fundamentals

	Return On Equity	0.46
	Return On Asset	0.0881
	Profit Margin	0.16 %
	Operating Margin	0.20 %
	Current Valuation	179.06 B
	Shares Outstanding	2.04 B
	Shares Owned By Institutions	14.85 %
	Number Of Shares Shorted	4.83 M
	Price To Earning	11.80 X
	Price To Book	4.96 X
	Price To Sales	2.75 X
	Revenue	30.33 B
	Gross Profit	19.92 B
	EBITDA	9.29 B
	Net Income	4.93 B
	Cash And Equivalents	3.72 B
	Cash Per Share	0.32 X
	Total Debt	18.02 B
	Debt To Equity	0.98 %
	Current Ratio	1.43 X
	Book Value Per Share	3.29 X
	Cash Flow From Operations	6.35 B
	Short Ratio	1.83 X
	Earnings Per Share	2.97 X
	Price To Earnings To Growth	1.09 X
	Target Price	45.39
	Number Of Employees	70.21 K
	Beta	0.27
	Market Capitalization	84.25 B
	Total Asset	59.01 B
	Retained Earnings	7.24 B
	Working Capital	(2.42 B)
	Current Asset	16.59 B
	Current Liabilities	13.42 B
	Annual Yield	0.04 %
	Five Year Return	5.32 %
	Net Asset	59.01 B
	Last Dividend Paid	0.58

About GlaxoSmithKline PLC Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

GlaxoSmithKline PLC Investors Sentiment

The influence of GlaxoSmithKline PLC's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in GlaxoSmithKline. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to GlaxoSmithKline PLC's public news can be used to forecast risks associated with an investment in GlaxoSmithKline. The trend in average sentiment can be used to explain how an investor holding GlaxoSmithKline can time the market purely based on public headlines and social activities around GlaxoSmithKline PLC ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

GlaxoSmithKline PLC's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for GlaxoSmithKline PLC's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average GlaxoSmithKline PLC's news discussions. The higher the estimated score, the more favorable is the investor's outlook on GlaxoSmithKline PLC.

GlaxoSmithKline PLC Implied Volatility

33.78

GlaxoSmithKline PLC's implied volatility exposes the market's sentiment of GlaxoSmithKline PLC ADR stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if GlaxoSmithKline PLC's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that GlaxoSmithKline PLC stock will not fluctuate a lot when GlaxoSmithKline PLC's options are near their expiration.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GlaxoSmithKline PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GlaxoSmithKline PLC's short interest history, or implied volatility extrapolated from GlaxoSmithKline PLC options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:

How To Invest In GlaxoSmithKline

Details

Is GlaxoSmithKline Stock a good investment?

Details

What is GlaxoSmithKline PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out GlaxoSmithKline PLC Piotroski F Score and GlaxoSmithKline PLC Altman Z Score analysis.

You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Complementary Tools for GlaxoSmithKline Stock analysis

When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.

	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	CEOs Directory Screen CEOs from public companies around the world
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity

Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.77)

Dividend Share

0.58

Earnings Share

2.97

Revenue Per Share

14.97

Quarterly Revenue Growth

0.092

The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Glaxosmithkline Plc Adr Stock Beta

GlaxoSmithKline PLC ADR Company Beta Analysis

Beta

Covariance

Variance

Current GlaxoSmithKline PLC Beta

GlaxoSmithKline Beta Driver Correlations

GlaxoSmithKline Beta Peer Comparison

GlaxoSmithKline PLC Current Valuation Drivers

GlaxoSmithKline PLC Institutional Holders

GlaxoSmithKline Fundamentals

About GlaxoSmithKline PLC Fundamental Analysis

GlaxoSmithKline PLC Investors Sentiment

GlaxoSmithKline PLC Implied Volatility

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for GlaxoSmithKline Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY